For instance, in prostate cancer diagnostics, DEP-based platforms have been used to target biomarkers such as prostate-specific antigen (PSA), human glandular kallikrein 2 (hK2), Annexin A3 (ANXA3), beta-2-microglobulin (β2M), microseminoprotein-beta (MSMB), serum amyloid A (SAA), and Engrailed-2 (EN2). This evidence concerns the gene EN2 and prostate carcinoma.